Inducible systems for studying liver tumor mainenance in vivo
用于研究肝脏肿瘤体内维持的诱导系统
基本信息
- 批准号:9457376
- 负责人:
- 金额:$ 7.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressBAY 54-9085Cancer EtiologyCessation of lifeClinical TrialsComplexCritical PathwaysDataDevelopmentDiseaseEIF4EBP1 geneEventFRAP1 geneGene ExpressionGenesGeneticGenetic EngineeringGoalsHepatocarcinogenesisInjectionsLeadLifeLiverLiver neoplasmsMAP Kinase GeneMYC geneMaintenanceMalignant NeoplasmsMalignant neoplasm of liverMediatingModelingMolecularMolecular GeneticsMusOncogenesPathogenesisPathway interactionsPatientsPrimary carcinoma of the liver cellsRaptorsResearchResearch Project GrantsRoleSDZ RADSignal PathwaySignal TransductionSirolimusSleeping BeautySolidStudy modelsSystemTechnologyTestingTransfectionbeta cateninc-myc Geneseffective therapyexperimental studyflexibilityin vivoinhibitor/antagonistinsightmouse modelneoplastic cellnovelnovel strategiesnovel therapeuticsoverexpressiontargeted treatmenttumortumor growthtumor initiationtumor progression
项目摘要
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death
worldwide. However, molecular genetics underlying HCC development remain to be poorly understood.
Treatment options for HCC are very limited and in general ineffective. There is only a single option for
treatment of advanced HCC (Sorafenib) which prolongs life by an average of just three months! Consequently,
there is a pressing unmet need for new insights on HCC that will lead to new therapies. The growing
understanding of molecular pathogenesis of HCC, on the other hand, does open the door for novel strategy of
targeted therapy. Hydrodynamic transfection combines hydrodynamic injection together with sleeping beauty
mediated somatic integration for long term gene expression. Because of its flexibility and high efficiency, it has
now becoming increasingly popular to be used to generate murine models for studying hepatocarcinogenesis.
However, so far few inducible systems have been established for this technology. Amplification and
overexpression of c-Myc oncogene is one of the most frequently observed genetic events during HCC
pathogenesis; and c-Myc is considered to be an important driver oncogene for HCC. Indeed overexpression of
c-Myc in mouse liver promotes the formation of poorly differentiated HCC. Recently, we discovered that
ablation of Raptor, the unique component of mTORC1, significantly suppressed c-Myc driven HCC
development in vivo. However, it is not clear whether mTORC1 is required for c-Myc HCC maintenance and
whether inhibition of mTORC1 leads to HCC regression. In this application, we hypothesize that mTORC1 is
required for c-Myc maintenance; and deleting Raptor after tumor formation will lead to tumor regression. In this
R03 small application, we will establish an efficient inducible Cre system for hydrodynamic transfection (Aim 1).
We will then apply the technology to delete Raptor in c-Myc induced HCC tumors in vivo with the goal to study
whether mTORC1 complex is required for maintaining c-Myc HCC (Aim 2). Altogether, this is a
self-contained
research projects which fits well with the description and scope of a R03 small research project. It assists to
develop a powerful research technology which can be used to characterize the requirement of a gene or
pathway for HCC maintenance. The results from such studies are critical for establishing the gene or
pathway for the treatment of HCC.
摘要
肝细胞癌(HCC)是第五大常见癌症,也是癌症死亡的第三大原因
国际吧然而,HCC发生的分子遗传学基础仍然知之甚少。
HCC的治疗选择非常有限,并且通常无效。只有一个选择,
治疗晚期肝癌(索拉非尼),平均寿命仅延长三个月!因此,委员会认为,
对HCC的新见解存在迫切的未满足的需求,这将导致新的疗法。日益增长的
另一方面,对HCC分子发病机制的了解确实为新的治疗策略打开了大门。
靶向治疗流体动力转染结合流体动力注射与睡美人
介导的体细胞整合用于长期基因表达。由于其灵活性和高效率,
现在越来越多地被用于产生研究肝癌发生的小鼠模型。
然而,到目前为止,很少有诱导系统已经建立了这项技术。扩增和
c-Myc癌基因的过度表达是HCC中最常见的遗传事件之一
c-Myc被认为是HCC的重要驱动癌基因。事实上,
小鼠肝脏中的c-Myc促进低分化HCC的形成。最近,我们发现,
消融mTORC 1的独特组分Raptor,可显著抑制c-Myc驱动的HCC
体内发育然而,目前尚不清楚mTORC 1是否是维持c-Myc HCC所必需的,
mTORC 1抑制是否导致HCC消退。在本申请中,我们假设mTORC 1是
c-Myc维持所必需的;并且在肿瘤形成后删除Raptor将导致肿瘤消退。在这
R 03的小应用,我们将建立一个高效的诱导型Cre系统用于流体动力学转染(目的1)。
然后,我们将应用该技术在体内c-Myc诱导的HCC肿瘤中删除Raptor,目的是研究
mTORC 1复合物是否是维持c-Myc HCC所必需的(目的2)。总之,这是一个
自包含
符合R 03小型研究项目的描述和范围的研究项目。它除了可以
开发一种强大的研究技术,可用于表征基因的需求,或
维持HCC的途径。这些研究的结果对于建立基因或
治疗HCC的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xin Chen其他文献
Xin Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xin Chen', 18)}}的其他基金
Investigating multifactorial beta-catenin activation in hepatocellular cancers
研究肝细胞癌中的多因素 β-连环蛋白激活
- 批准号:
10541171 - 财政年份:2022
- 资助金额:
$ 7.93万 - 项目类别:
Investigating multifactorial beta-catenin activation in hepatocellular cancers
研究肝细胞癌中的多因素 β-连环蛋白激活
- 批准号:
10574374 - 财政年份:2022
- 资助金额:
$ 7.93万 - 项目类别:
Investigating multifactorial beta-catenin activation in hepatocellular cancers
研究肝细胞癌中的多因素 β-连环蛋白激活
- 批准号:
10326862 - 财政年份:2021
- 资助金额:
$ 7.93万 - 项目类别:
Cabozentinib based combination therapy for the treatment of hepatocellular carcinoma
基于卡博替尼的联合疗法治疗肝细胞癌
- 批准号:
10117217 - 财政年份:2020
- 资助金额:
$ 7.93万 - 项目类别:
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
癌症相关成纤维细胞在胆管癌中的作用
- 批准号:
10166796 - 财政年份:2018
- 资助金额:
$ 7.93万 - 项目类别:
Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
癌症相关成纤维细胞在胆管癌中的作用
- 批准号:
10414782 - 财政年份:2018
- 资助金额:
$ 7.93万 - 项目类别:
Yap and beta-catenin interactions in liver: Implications in Pathophysiology
Yap 和 β-连环蛋白在肝脏中的相互作用:对病理生理学的影响
- 批准号:
9901472 - 财政年份:2016
- 资助金额:
$ 7.93万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Research Grant














{{item.name}}会员




